Matching at Human Leukocyte Antigen-C Improved the Outcomes after Double Umbilical Cord Blood Transplantation for Recipients of Two to Four of Six Human Leukocyte Antigen-Matched Grafts

Biol Blood Marrow Transplant. 2017 Jan;23(1):126-133. doi: 10.1016/j.bbmt.2016.10.018. Epub 2016 Oct 29.

Abstract

We studied the effect of HLA-C matching in 515 patients after double umbilical cord blood (UCB) transplantation. After HLA matching HLA-A, -B, and -DRB1 at the allele level, we scored patients according to number of donor-recipient HLA-C matches at 4 possible loci: 2 from each donor unit, at the allele level. Given a direct interaction between HLA-A, -B, and -DRB1 matching and HLA-C score, we analyzed HLA-C matching in those receiving at least 1 2/6 to 4/6 HLA-matched unit (n = 389) versus those receiving only 5/6 or 6/6-matched units (n = 126). In those with at least 1 2/6 to 4/6 HLA-matched unit, a better HLA-C matching score was associated with significantly lower risk of death of any cause and nonrelapse mortality and better disease-free survival. There was no association with the risk of relapse, acute and chronic graft-versus-host disease, and hematopoietic recovery. In contrast, among patients receiving only allele-level 5/6 or 6/6 HLA-matched UCB units, HLA-C match had no demonstrable effect on any outcome. For patients receiving at least 1 allele-level 2/6 to 4/6 HLA-matched UCB unit, matching at HLA-C reduces nonrelapse mortality and improves survival.

Keywords: Alternative donor transplantation; Double umbilical cord blood; Human leukocyte antigen.

Publication types

  • Multicenter Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Child
  • Child, Preschool
  • Cord Blood Stem Cell Transplantation / methods*
  • Cord Blood Stem Cell Transplantation / mortality
  • Female
  • Graft vs Host Disease / complications
  • Graft vs Host Disease / etiology
  • HLA-C Antigens* / analysis
  • HLA-C Antigens* / immunology
  • Hematologic Neoplasms / mortality
  • Hematologic Neoplasms / therapy
  • Histocompatibility Testing*
  • Humans
  • Male
  • Middle Aged
  • Recurrence
  • Retrospective Studies
  • Transplants / immunology
  • Treatment Outcome
  • Young Adult

Substances

  • HLA-C Antigens